特發(fā)性肺纖維化是由不明原因引起的疾病，目前還沒有一種藥物來有效治療該疾病。吡非尼酮是一類吡啶類的小分子物質(zhì)，通過抑制轉(zhuǎn)化生長(zhǎng)因子-β，改變膠原合成和累積，抑制細(xì)胞外基質(zhì)增殖和表達(dá)，具有抗炎、抗氧化和抗纖維化的作用。在一系列的臨床試驗(yàn)中，顯示了吡非尼酮是潛在治療特發(fā)性纖維化的藥物，具有良好的應(yīng)用前景。

Idopathic pulmonary fibrosis (IPF) is a disease caused by unknown reason. To date, there is no one drug to effectively treat the disease. Pirfenidone is an anti-inflammatory, anti-oxidant, and antifibrotic angent that inhibits transforming growth factor-β in vitro and changes collagen synthesis and accumulation, and inhibits proliferation and extracellular matrix expression. In a series of clinical trials, pirfenidone is a potential for the treatment of IPF.